SYNCHRONOUS ANAL MELANOMA AND COLON ADENOCARCINOMA: CASE REPORT AND REVIEW OF DIAGNOSIS AND MANAGEMENT

Citation

Published Version
doi:10.1590/0102-6720201600040020

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:30371007

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
SYNCHRONOUS ANAL MELANOMA AND COLON ADENOCARCINOMA: CASE REPORT AND REVIEW OF DIAGNOSIS AND MANAGEMENT

Melanoma anal e adenocarcinoma de colon sincrônicos: relato de caso e revisão de diagnóstico e conduta

Eduardo Henrique Pirolla1, Felipe Piccarone Gonçalves Ribeiro1, Fernanda Junqueira Cesar Pirola1, Camila Cosmo2, Melany Di Biasi3

From the 1Harvard Medical School, Boston, Massachusetts, USA; 2Postgraduate Program in Interactive Process of Organs and Systems, Federal University of Bahia, Salvador, Bahia, Brazil; and 3Center for Technological Innovation in Rehabilitation, Federal University of Bahia, Salvador, Bahia, Brazil

HEADINGS – Melanoma. Adenocarcinoma. Diagnosis
DESCRITORES - Melanoma. Adenocarcinoma. Diagnóstico

Correspondence: Eduardo Henrique Pirolla
E-mail: eduardopirolla@gmail.com

Financial source: none
Conflicts of interest: none
Received for publication: 04/02/2016
Accepted for publication: 02/08/2016

INTRODUCTION

Malignant anal melanoma is a rare disorder, corresponding to 0.05-1.0% of all anorectal tumors, and 0.4-1.6% of all other melanomas. Its rarity can be confirmed by the fact that for every anal melanoma, there are eight squamous cell carcinomas and 250 anal adenocarcinomas.

The article’s aim is to present a case of a malignant anal melanoma coexisting with colon adenocarcinoma, in addition to a discussion on how to speed up the diagnosis with simple routine measures, and report an objective treatment.

CASE REPORT

A 57-year-old patient was admitted with weakness, pale skin and a lump in the inguinal region. According to his medical history, one year prior to admittance the patient was treated for anemia. At the time, he presented positive fecal occult blood test. Endoscopy and contrast exams were normal and no weight loss or changes in bowel movements were noticed.

In the six months prior to admittance, the patient felt sporadic pain in the anal canal that ceased with the use of NSAID suppositories. After 30 days, he sought medical attendance and underwent proctosigmoidoscopy and colonoscopy, along with biopsy of lesions in the anal canal and cecum. The patient was then diagnosed with poorly differentiated carcinoma of the canal and well differentiated tubular adenocarcinoma of the cecum. At the time, a lump began forming in the root of the thigh, just below the inguinal fold.

The patient was referred to Sírio-Libanês Hospital in São Paulo, Brazil, for surgical treatment of the colon lesion and clinical treatment of the anal canal lesion (Figure 1), as he refused to operate the anal lesion. Abdominal ultrasonography and thorax tomography did not reveal any findings. Surgery was then performed with right ileocecal colectomy, intra-operative biopsy of lesion in the anal canal and of the right inguinal lymph node.

Anatomopathological findings of the anal canal revealed an amelanotic malignant melanoma with extensive infiltration and presence of ulcerations and necrosis (Figure 2); right inguinal lesion was a metastatic amelanotic malignant melanoma.

Findings on the colon lesion revealed a segment of the left colon had histological stage II invasive tubular adenocarcinoma, a presence of 20% of mucous membrane, diffuse and extensive infiltration of the colon wall up to the peripheral adipose tissue, ulcerative lesion with irregular areas and necrosis, discreet fibrosis and inflammatory infiltration, and absence of vascular or peri-neural invasion. The anatomopathological examination of surgical borders revealed absence of neoplasm. Assessment of mesocolic lymph nodes exhibited reactive lymphoid hyperplasia with no metastasis (0/13).

The patient refused surgical treatment on the anal canal and neglected follow-up. After two months, he returned with exophytic lesion and bleeding, along with significant loss of weight and pain. In the 6th day prior to hospitalization, there was a new episode of bleeding, which led to hospitalization. A new
abdominal tomography showed multiple adenomegalies in the paraaortic, paracaval, inguinal, and bilateral perirectal lymph nodes. It also revealed a heterogenic mass with imprecise limits; compatible with ganglion conglomerates of mesenteric origin, next to the hepatic angle of the colon; presence of a soft tissue mass in the anal canal, extending to the ischiorectal fossa towards the perineal border, predominantly on the left, with no dividing plane with the elevator muscle of the anus. Due to the bleeding and ulceration, a colonostomy was performed and local radiotherapy began. After the third session of 300 rads in each there was significant improvement of the bleeding, which stopped after the fourth session. There was clinical improvement and the patient is currently undergoing monitoring.

**DISCUSSION**

Malignant anorectal melanoma was first described by Moore in 1857. The origin of the tumor appears to be ectodermic, although the presence of melanocytes in the colorectal, above the squamous and transitional regions of the anal canal, proves that the tumor can originate above just as bellow the pectinate line. Some authors argue that, in almost all cases, the tumor originates in the pectinate line and grows in the submucous space, scrolling through the tissue to emerge on the mucosa at a higher point, thus simulating a primary rectal tumor. The prognosis is poor since the survival rate is low. Some authors relate this to a late diagnosis in most cases. The early signs and symptoms are similar to other colorectal diseases, being most frequent anal bleeding, local pain, changes in bowel habits, and in many times, the growth of lumps in the region. The difficulty in diagnosing is brought by the similarities of the symptoms with hemorrhoidal disease or anal fissure, as well as the fact that in 16-41% of lesions lack pigmentation. The incidence is greater in women. The average age group consists of patients in their sixties and seventies. Resection is the treatment of choice among the authors depending on the size of the lesion. The level of infiltration and presence of metastases are some of the factors considered when choosing the extension of resection. Previous or adjuvant postoperative radiotherapy and chemotherapy is very debatable.

Many authors believe that the origin of these tumors is in the dentate line, where melanocytes have been detected. Iron ions have been used for staining, currently; the Masson-Fontana technique is used to show melanocytes above the dentate line. The most up-to-date techniques use immunohistochemical reactions such as S-100 protein (antibodies S-100), which has greater sensitivity, but less specificity. Monoclonal antibodies are also used as a detection method, such as HMB-45 (monoclonal Enzo). The Breslow classification is best used to classify the depth of the tumor. This method is preferred to the Clark classification, regarding the lack of papillary dermis in the region.

Many authors classify anorectal melanomas in stages; the most common being: stage I – in situ; stage II – regional spread (inguinal lymphadenopathy); stage III – metastasis. The metastasis areas can be arranged according to its frequency: lungs, bones, liver, brain and gastrointestinal tract. The early diagnosis is essential to improve the prognosis of such an aggressive disease. Survival rates vary from 6-12% for five years. The average survival rate in literature is 18 months.

Some factors can worsen the prognosis such as late diagnosis, ulceration, rich mucous vascularization, and aggressive nature of the tumors.

Since the most common complaints are enterorrhagia and anal bleeding, it is essential to perform a proctosigmoidoscopy and biopsy. The pathologist should be reminded of the hypotheses, for there might be difficulties in differential diagnosis of anaplastic carcinoma and hemorrhoidal disease. It is essential to obtain other anatopathological evidence. Some authors recommend using contrast exams along with colonoscopy. The malignant anorectal melanoma presents early metastases. Mesenteric lymph nodes involvement is more common than inguinal. Rectum lesions drain to the mesorectal lymph nodes and to the inferior mesenteric chain, which can occur in 33.3% of the cases. Cutaneous anal lesions drain to the superficial inguinal lymph nodes. The dissemination through hematogenous pathway can reach the liver, lungs, bones, brain and gastrointestinal tract. Authors diverge regarding conduct and treatment, although the recommended procedure is surgery, there are debates regarding local excision or abdominoperineal resection, and another group of authors that indicates radiotherapy and/or chemotherapy to control signs and symptoms, such as bleeding, regarding intracavitary and inguinal lymph nodes.

For some authors, abdominoperineal resection can lead to a greater survival rate, especially if there is no lymph node invasion (Stage I).

The great majority of authors did not show significant difference in survival rate in patients referred to abdominoperineal resection and local excision. There is some consensus on the fact that less recurrence is observed when abdominoperineal resection is performed, but with no statistical significant. Another aspect is that patients without compromised lymph nodes who are refered to abdominoperineal resection have a more favorable prognosis when compared to cases with compromised lymph nodes. Some authors believe that the prognosis is strictly related to the aggressive nature and early surgery.

Regarding adjuvant treatments, literature contests the success of radiotherapy (anorectal muscle non-responsiveness), as well as the lack of clarity of chemotherapy success. Radiotherapy and hyperthermia is mentioned to control in situ disease, followed by a regression of the tumor. Radiotherapy is not the treatment of choice, but it can be used as palliative treatment. Immunotherapy is another method, being administered to patients that become surgically free (macroscopically) of the disease. This treatment is carried out for 4-7 months with subcutaneous injections of irradiated melanocytes with Calmette-guerin bacilli.

In conclusion, studies show the highly aggressive nature of the tumor, and the difficulty in early diagnosis and initial clinical staging. The prognosis is poor and patients face challenging metastases. Surgical outcomes are mediocre and very few live over five years.

**REFERENCES**

CENTRAL HEPATECTOMY FOR BILIARY CYSTADENOMA: PARENCHYMA-SPARING APPROACH FOR BENIGN LESIONS

Hepatectomia central para cistoadenoma biliar: preservação de parênquima em lesões benignas

Raphael L. C. Araujo1, Danielle Cesconetto1, Vagner Birk Jeismann1, Gilton Marques Fonseca1, Fabício Ferreira Coelho1, Jaime Arthur Pirola Kruger1, Paulo Herman1

From the 1Liver Surgery Unit, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, SP; 2Department of Upper GI and HPB Surgery, Barretos Cancer Hospital, Barretos, SP, Brazil

INTRODUCTION

Central hepatectomy (CH) is also known as mesohepatectomy and means hepatic resection of segments 4, 5, and 8. Hepatic lesions located in these segments may require extensive resections, such as right, left, extended right or extended left hemi-hepatectomies especially due to their relationship to major vascular and biliary structures. CH represents a potential risk of intraoperative bleeding, biliary injury, and risk of positive margins, but also represent the appealing concept of parenchyma sparing, furthermore in benign lesions.

CASE REPORT

A 61-year old female patient with history of choluria, acholic stools, jaundice and pain in the right upper abdominal quadrant had undergone a cholecystectomy and hepatic cyst unroofing by laparotomy in another institution, 30 months ago. Due to the cholestatic symptoms recurrence, she was referred to our center.

Abdominal MRI showed a cystic lesion in segment 4 with septa and thickened walls, and measuring 9.0 cm. The cyst was demonstrated as isosignal on T1 and hyperintense signal on T2. The confluence of left and right bile ducts was compressed by the cyst, which caused moderate bilateral dilation. The lateral limit of the cyst compressed the left hepatic artery and the left branch of the portal vein, while its lower limit compressed the right portal branch and the right hepatic artery. Other non-complex cystic lesions were scattered throughout the liver (Figure 1). Laboratory tests showed increased canicular enzymes and bilirubins and negative tumor markers. The case was reviewed at a weekly hepatobiliary multidisciplinary conference and the main hypothesis was a recurred biliary cystadenoma. In order to avoid a right trisectionectomy the decision was to perform a parenchymal preserving resection - central hepatectomy.

During surgery, was confirmed the close relationship of the cyst and the hilar plate. Intraoperative ultrasound showed compression but not invasion of the hilar plate. The liver inflow was controlled with ultrasonic dissector and bipolar electrocaukulation, as demonstrated in Figures 2 and 3. Parenchyma transection was carried out with intermittent pedicle clamping (Pringle’s maneuver). No blood transfusion was necessary. The postoperative course was only marked by a low volume biliary fistula conservatively managed with cavity drain placed during surgery (grade I – Dindo & Clavien classification). She was discharged on 8th postoperative day.

Pathological examination revealed a biliary cystadenoma presenting low-grade neoplasia with free margins. After 18 months of follow-up, the patient is doing well without either symptomatic or radiological recurrence (Figure 4).

DISCUSSION

CH is also known as mesohepatectomy, central hepatic resection, middle hepatectomy, middle hepatic lobectomy, and central bisectionectomy. The putative risks of it compared to traditional major liver resections include a longer procedure time, greater intraoperative blood loss, higher risk of biliary and vascular complications, all mainly attributed to the proximity to hilar structures and the presence of two significant resection planes instead of a single one. Despite those concerns, this case highlighted that CH is safe and can be accomplished without significant morbidity. No significant differences for postoperative morbidity and mortality between CH and extend hepatectomy (EH) were demonstrated by Lee’s systematic review. Additionally, a recent case-matched study from the same author showed no differences in 90-day mortality, biliary leaks and postoperative liver failure. Moreover, this study also showed longer length of stay, higher postoperative bilirubin and longer prothrombine time for patients who underwent extend hepatectomy.

Liver parenchyma sparing aims to decrease the risk of postoperative liver failure, shorten recovering time, and allow re-hepatectomies in patients with high risk of recurrence. In patients with multifocal benign (adenomatosis) or malignant complex cystic tumor who underwent a CH without tumor violation and no major postoperative complication.